Amendments to the Specification

Please insert the following paragraph at page 9, line 3 of the specification.

Examples of salts of the compounds of the present invention include (3*S*,4a*R*,6*R*,8a*R*)-6-[2-(1H-Tetrazol-5-yl)-ethyl] -1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid 2-ethyl-butyl ester trifluoroacetate salt; (3*S*,4a*R*,6*R*,8a*R*)-6-[2-(1H-Tetrazol-5-yl)-ethyl] -1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid isobutyl ester trifluoroacetate salt; (3*S*,4a*R*,6*R*,8a*R*)-6-[2-(1H-Tetrazol-5-yl)-ethyl] -1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid 3-methyl butyl ester trifluoroacetate salt; (3*S*,4a*R*,6*R*,8a*R*)-6-[2-(1H-Tetrazol-5-yl)-ethyl] -1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid decyl ester trifluoroacetate salt; and (3*S*,4a*R*,6*R*,8a*R*)-6-[2-(1H-Tetrazol-5-yl)-ethyl] -1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid ethyl ester hydrochloride salt.

Please replace the paragraph that appears at page 18, line 24 through page 19, line 4, with the following paragraph, marked up to reflect amendments made:

Male Fischer Rats are administered either an oral or iv dose of (3*S*,4a*R*,6*R*,8a*R*)-6-[2-(1(2)*H*-tetrazole-5-yl)ethyl-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid ~~(30 mg/Kg p.o;~~ 10mg/Kg ~~i.v.~~) to determine oral bioavailability. A separate group of rats are administered an oral 10 mg/kg dose of an ester prodrug (for example (3*S*,4a*R*,6*R*,8a*R*)-6-[2-(1(2)*H*-tetrazole-5-yl)ethyl-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid ethyl ester, HCL salt) to determine whether the prodrug would increase bioavailability of the parent acid. The plasma concentrations of (3*S*,4a*R*,6*R*,8a*R*)-6-[2-(1(2)*H*-tetrazole-5-yl)ethyl-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid are determined by LC/MS/MS.

Please delete the paragraph that appears at page 19, line 6 through line 14.

Please replace the paragraph that appears at page 19, line 25 through line 27 with the following paragraph, marked up to reflect the amendments made:

Tables 2 below summarizes the pharmacokinetic parameters found for Compounds A and B ~~following 10 mg/kg administration (i.v.) or 30 mg/kg administration (p.o.) to Fischer Rats~~.

Please replace the paragraph, including the table, that appears at page 19, line 30 through page 20, line 1 with the following, marked up to show amendments made (Note: The table heading is correct and was underscored in the specification as originally filed):

Table 2. Pharmacokinetic Parameters of Compound A in Fischer Rats after a 10 mg/kg Dose of Compound A or the ester Prodrug, Compound B.*

Compound	T_{max} (hr)	C_{max} (ng/mL)	AUC (ng hr/mL)	% Bioavail	Improvement
A (acid), i.v. ~~(10 mg/kg)~~	-	11,022	6,727	-	
A (acid), p.o. ~~(30 mg/kg)~~		93	241	3.6	1
B (ester), p.o. ~~(30 mg/kg)~~		265	1,192	17.7	~5X